Dalma Dobszai

Dalma Dobszai

Auto-generated profile, based on publicly available information

Dalma Dobszai

Institute for Translational Medicine Medical School University of Pécs Pécs Hungary

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2024 in United European Gastroenterology Journal
Verified
Journal Article
Open access
RBRuben Zsolt Borbély
Ruben Zsolt Borbély
ESEszter Ágnes Szalai
Eszter Ágnes Szalai
BPBryan Mangalath Philip
Bryan Mangalath Philip
DDDalma Dobszai
Dalma Dobszai
BTBrigitta Teutsch
Brigitta Teutsch
NFNándor Faluhelyi
Nándor Faluhelyi
Background: Splanchnic vein thrombosis is a complication of acute pancreatitis (AP) and is likely often underdiagnosed.Objectives: We aimed to understand the time course and risk factors of splanchnic vein thrombosis in the early phase of AP.Methods: A systematic search was conducted using the PRISMA guidelines (PROSPERO registration CRD42022367578). Inclusion criteria were appropriate imaging techniques in adult AP patients, studies that reported splanchnic vein thrombosis data from the early phase, and reliable information on the timing of imaging in relation to the onset of pancreatitis symptoms or hospital admission. The proportion of patients with thrombosis with 95% confidence intervals (CI) was calculated using random‐effects meta‐analyses, and multiple subgroup analyses were performed.Results: Data from 1951 patients from 14 studies were analyzed. The proportion of patients with splanchnic vein thrombosis within 12 days after symptom onset was 0.13 (CI 0.07–0.23). The occurrence was lowest at 0.06 (CI 0.03–0.1) between 0 and 3 days after symptom onset, and increased fourfold to 0.23 (CI 0.16–0.31) between 3 and 11 days. On hospital admission, the proportion of patients affected was 0.12 (CI 0.02–0.49); it was 0.17 (CI 0.03–0.58) 1–5 days after admission. The prevalence in mild, moderate, and severe AP was 0.15 (CI 0.05–0.36), 0.26 (CI 0.15–0.43), and 0.27 (CI 0.17–0.4), respectively. Alcoholic etiology (0.31, CI 0.13–0.58) and pancreatic necrosis (0.55, CI 0.29–0.78, necrosis above 30%) correlated with increased SVT prevalence.Conclusion: The risk of developing splanchnic vein thrombosis is significant in the early stages of AP and may affect up to a quarter of patients. Alcoholic etiology, pancreatic necrosis, and severity may increase the prevalence of splanchnic vein thrombosis.

6 November 2026 in United European Gastroenterology Journal
Verified
Journal Article
Open access
VVViktória Venglovecz
Viktória Venglovecz
ZAZsolt Abonyi-Tóth
Zsolt Abonyi-Tóth
PSPetra Széplaki
Petra Széplaki
VVVivien Vass
Vivien Vass
DDDalma Dobszai
Dalma Dobszai
Peter HegyiPeter Hegyi
Peter Hegyi
Background: We previously proposed that three or more episodes of acute pancreatitis (AP) without radiological evidence of CP constitute early chronic pancreatitis (ECP), but it remains unclear whether ECP represents advanced recurrent acute pancreatitis (RAP) or a distinct clinical stage. Methods: We performed a post hoc analysis of prospectively collected data from the AP Registry of the Hungarian Pancreatic Study Group, including 1717 patients enrolled between 2017 and 2025. Patients were categorized as AP (single episode; n = 1143), RAP (two episodes without CP morphology; n = 215), ECP (≥ 3 episodes without CP morphology; n = 152), or acute‐on‐chronic pancreatitis (ACP; radiological CP with at least one AP episode; n = 207). Demographic characteristics, risk factors, outcomes, and endoscopic interventions were compared across the groups. Results: Male predominance increased progressively from RAP (58%) to ECP (72%) and ACP (79%). Similarly, alcohol‐related etiology rose from 23% in RAP to 36% in ECP and 45% in ACP. Smoking prevalence increased markedly from 36% in RAP to 49% in ECP and 68% in ACP. A change in therapeutic indications became apparent in ECP. While endoscopic interventions in AP and RAP were predominantly prophylactic (71% and 67%, respectively), pancreatic duct–directed procedures emerged as a leading indication in ECP (42%) and became dominant in ACP (77%), consistent with increasing pancreatic duct involvement across disease stages. Conclusions: ECP represents a distinct transitional phenotype between RAP and established CP and already exhibits characteristic epidemiological, etiological, and therapeutic features. Recognition of ECP may therefore identify a critical window for targeted intervention before irreversible morphological damage to the pancreas occurs.